TriAxia Health Partners with Leading Academic Medical Centers on Rare Pulmonary Disease Pilot

Share Article

Illumina Accelerator company TriAxia Health, in partnership with Harvard/The Brigham and Women's Hospital, The University of Pittsburgh/UPMC, and the University of Arizona/Banner-University Medicine, announces launch of a digital health platform for rare disease patients with a pilot in rare pulmonary diseases

News Image
By combining clinical and molecular data at a patient level, from multiple different care settings, and leveraging the latest in machine learning and artificial intelligence, we hope to provide significant new understanding of which treatments are most effective for which patients, and why

TriAxia Health Partners with Leading Academic Medical Centers on Rare Pulmonary Disease Pilot

TriAxia Health, Inc., a Boston-based digital health company with a mission to improve health outcomes for patients living with rare diseases, will collaborate with Harvard Medical School-affiliated Brigham and Women’s Hospital, The University of Pittsburgh and its clinical partner UPMC and the University of Arizona Health Sciences and its clinical partner Banner – University Medicine to develop a rare pulmonary disease pilot of the TriAxia Health platform.

This first-of-its-kind effort will combine clinical data from each of the hospitals with tailored molecular data sequenced from patients (from both DNA and RNA) with a goal of developing new insights into the progression and treatment of rare pulmonary diseases, starting with pulmonary arterial hypertension (PAH). All analysis will be done with de-identified data, using data and samples from patients who consented to participate, and in compliance with the various hospitals’ Institutional Review Boards (IRB) guidance.

“By combining clinical and molecular data at a patient level, from multiple different care settings, and leveraging the latest in machine learning and artificial intelligence, we hope to provide significant new understanding of which treatments are most effective for which patients, and why,” said Aaron Waxman, MD, PhD, the director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital, and chair of the TriAxia Health rare pulmonary disease Scientific Advisory Board (SAB).

“The only way to effectively understand rare disease patients is to aggregate their clinical data from multiple hospitals, since each hospital provides care differently, and no one hospital has enough of these patients to power research,” said Simon Kennedy, CEO of TriAxia Health. “We at TriAxia Health are thrilled to be partnering with these leading academic medical centers to help build the largest, most comprehensive global data set ever for these diseases, combining both clinical and genomic data, to ensure that patients living with rare diseases receive the most effective treatment, and to enable new treatments by providing new insights about rare diseases.”

TriAxia Health completed the Illumina Accelerator in 2019. For more information about TriAxia Health, please visit our website at http://www.TriAxiaHealth.com

About TriAxia Health
Our mission is to improve health outcomes for patients living with rare diseases by enabling the selection and discovery of the most effective treatments for each patient. We do so through collaboration across leading hospital systems, the integration of clinical and genomic patient information, and the application of cutting-edge AI. You can follow us on Twitter and LinkedIn

Media Contact
Simon Kennedy – Simon@TriAxiaHealth.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Simon Kennedy
@TriAxiaHealth
since: 10/2019
Follow >
Visit website